Eric J Feuer

List of Publications by Year
in descending order

66 papers	17,332 citations	76322 40 h-index	106340 65 g-index
68 all docs	68 docs citations	68 times ranked	19776 citing authors

#	Article	IF	Citations
1	Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. Journal of Thoracic Oncology, 2022, 17, 160-166.	1.1	20
2	Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality. BMC Public Health, 2022, 22, 141.	2.9	9
3	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. JAMA - Journal of the American Medical Association, 2021, 325, 988.	7.4	181
4	Updated Methodology for Projecting U.S.- and State-Level Cancer Counts for the Current Calendar Year: Part I: Spatio-temporal Modeling for Cancer Incidence. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1620-1626.	2.5	6
5	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2001-2009.	2.5	9
6	Updated Methodology for Projecting U.S.- and State-Level Cancer Counts for the Current Calendar Year: Part II: Evaluation of Incidence and Mortality Projection Methods. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1993-2000.	2.5	9
7	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. Journal of the National Cancer Institute, 2020, 112, 154-160.	6.3	27
8	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. Journal of the National Cancer Institute, 2020, 112, 466-479.	6.3	67
9	The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine, 2020, 383, 640-649.	27.0	893
10	Disparities of National Lung Cancer Screening Guidelines in the US Population. Journal of the National Cancer Institute, 2020, 112, 1136-1142.	6.3	48
11	Small Area Estimation of Cancer Risk Factors and Screening Behaviors in US Counties by Combining Two Large National Health Surveys. Preventing Chronic Disease, 2019, 16, E119.	3.4	12
12	Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20â€"49 Years. Journal of the National Cancer Institute, 2019, 111, 1279-1297.	6.3	219
13	Using Patient Preferences to Determine Noninferiority Margins in Trials. JAMA - Journal of the American Medical Association, 2019, 322, 2137.	7.4	0
14	Evidence-based sizing of non-inferiority trials using decision models. BMC Medical Research Methodology, 2019, 19, 3.	3.1	6
15	Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. BMJ Open, 2018, 8, e019169.	1.9	31
16	Variance Estimation and Confidence Intervals for 11 Commonly Used Health Disparity Measures. JCO Clinical Cancer Informatics, 2018, 2, 1-19.	2.1	10
17	Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Annals of Internal Medicine, 2018, 169, 684.	3.9	150
18	Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1370-1379.	6.3	31

#	Article	IF	Citations
19	Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer, 2018, 124, 2801-2814.	4.1	200
20	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer, 2017, 140, 2436-2443.	5.1	36
21	Annual Report to the Nation on the Status of Cancer, 1975â€"2014, Featuring Survival. Journal of the National Cancer Institute, 2017, 109, .	6.3	1,135
22	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	3.9	160
23	Urban/Rural Differences in Breast and Cervical Cancer Incidence: The Mediating Roles of Socioeconomic Status and Provider Density. Women's Health Issues, 2017, 27, 683-691.	2.0	64
24	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Medicine, 2017, 14, e1002277.	8.4	216
25	Development, Feasibility, and Small-Scale Implementation of a Web-Based Prognostic Toolâ€"Surveillance, Epidemiology, and End Results Cancer Survival Calculator. JMIR Cancer, 2017, 3, e9.	2.4	10
26	Health-Care Utilization by Prognosis Profile in a Managed Care Setting: Using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC. Journal of the National Cancer Institute Monographs, 2014, 2014, 275-281.	2.1	5
27	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer, 2014, 120, 1713-1724.	4.1	65
28	The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: Validation in a Managed Care Setting. Journal of the National Cancer Institute Monographs, 2014, 2014, 265-274.	2.1	17
29	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 997-1006.	2.5	61
30	Patterns of Birth Cohortâ€"Specific Smoking Histories, 1965â€"2009. American Journal of Preventive Medicine, 2014, 46, e31-e37.	3.0	150
31	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	3.9	123
32	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 160, 311.	3.9	377
33	Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients. Journal of Clinical Epidemiology, 2013, 66, 1376-1385.	5.0	52
34	Assessing Nonâ€"Cancer-Related Health Status of US Cancer Patients: Other-Cause Survival and Comorbidity Prevalence. American Journal of Epidemiology, 2013, 178, 339-349.	3.4	120
35	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975â€"2000. Journal of the National Cancer Institute, 2012, 104, 541-548.	6.3	145
36	<i>Chapter 3</i>: Cohort Life Tables by Smoking Status, Removing Lung Cancer as a Cause of Death. Risk Analysis, 2012, 32, S25-38.	2.7	44

#	Article	IF	Citations
37	*Chapter 2*: Birth‐Cohort‐Specific Estimates of Smoking Behaviors for the U.S. Population. Risk Analysis, 2012, 32, S14-24.	2.7	61
38	*Chapter 1*: The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality, 1975–2000: An Introduction to the Problem. Risk Analysis, 2012, 32, S6-S13.	2.7	15
39	The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer, 2012, 118, 5652-5662.	4.1	32
40	Predicting US‐and state‐level cancer counts for the current calendar year. Cancer, 2012, 118, 1091-1099.	4.1	44
41	Predicting US‐and state‐level cancer counts for the current calendar year. Cancer, 2012, 118, 1100-1109.	4.1	48
42	Dynamic Microsimulation Models for Health Outcomes. Medical Decision Making, 2011, 31, 10-18.	2.4	144
43	Productivity Savings from Colorectal Cancer Prevention and Control Strategies. American Journal of Preventive Medicine, 2011, 41, e5-e14.	3.0	28
44	Projections of the Cost of Cancer Care in the United States: 2010-2020. Journal of the National Cancer Institute, 2011, 103, 117-128.	6.3	2,151
45	Estimating average annual per cent change in trend analysis. Statistics in Medicine, 2009, 28, 3670-3682.	1.6	629
46	Modelling Population-Based Cancer Survival Trends by using Join Point Models for Grouped Survival Data. Journal of the Royal Statistical Society Series A: Statistics in Society, 2009, 172, 405-425.	1.1	21
47	Weighted Normal Spatial Scan Statistic for Heterogeneous Population Data. Journal of the American Statistical Association, 2009, 104, 886-898.	3.1	55
48	Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738.	3.9	509
49	Productivity Costs of Cancer Mortality in the United States: 2000–2020. Journal of the National Cancer Institute, 2008, 100, 1763-1770.	6.3	212
50	Combining Information From Two Surveys to Estimate County-Level Prevalence Rates of Cancer Risk Factors and Screening. Journal of the American Statistical Association, 2007, 102, 474-486.	3.1	96
51	Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer, 2007, 109, 1877-1886.	4.1	81
52	A New Method of Estimating United States and State-level Cancer Incidence Counts for the Current Calendar Year. Ca-A Cancer Journal for Clinicians, 2007, 57, 30-42.	329.8	86
53	Chapter 1: Modeling the Impact of Adjuvant Therapy and Screening Mammography on U.S. Breast Cancer Mortality Between 1975 and 2000: Introduction to the Problem. Journal of the National Cancer Institute Monographs, 2006, 2006, 2-6.	2.1	26
54	Chapter 15: Impact of Adjuvant Therapy and Mammography on U.S. Mortality From 1975 to 2000: Comparison of Mortality Results From the CISNET Breast Cancer Base Case Analysis. Journal of the National Cancer Institute Monographs, 2006, 2006, 112-121.	2.1	59

#	Article	IF	Citations
55	Geographic association between mammography use and mortality reduction in the US. Cancer Causes and Control, 2005, 16, 691-699.	1.8	20
56	The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing. Statistical Methods in Medical Research, 2004, 13, 421-442.	1.5	39
57	An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States. American Journal of Epidemiology, 2004, 160, 1059-1069.	3.4	36
58	A New Method of Predicting US and State-Level Cancer Mortality Counts for the Current Calendar Year. Ca-A Cancer Journal for Clinicians, 2004, 54, 30-40.	329.8	56
59	Cancer Statistics, 2004. Ca-A Cancer Journal for Clinicians, 2004, 54, 8-29.	329.8	3,622
60	Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. Journal of the National Cancer Institute, 2002, 94, 1626-1634.	6.3	126
61	Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer, 2002, 95, 870-880.	4.1	32
62	Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine, 2000, 19, 335-351.	1.6	3,877
63	Does Size Matter? Association Between Number of Patients Treated and Patient Outcome in Metastatic Testicular Cancer. Journal of the National Cancer Institute, 1999, 91, 816-818.	6.3	42
64	Cancer Surveillance Series: Interpreting Trends in Prostate CancerÂPart II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality. Journal of the National Cancer Institute, 1999, 91, 1025-1032.	6.3	211
65	The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes and Control, 1998, 9, 519-527.	1.8	131
66	How Much of the Recent Rise in Breast Cancer Incidence Can Be Explained by Increases in Mammography Utilization?. American Journal of Epidemiology, 1992, 136, 1423-1436.	3.4	131